351 related articles for article (PubMed ID: 24361258)
1. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G
Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258
[TBL] [Abstract][Full Text] [Related]
2. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
[TBL] [Abstract][Full Text] [Related]
9. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
[TBL] [Abstract][Full Text] [Related]
10. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
[TBL] [Abstract][Full Text] [Related]
12. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
13. Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer.
Foj L; Filella X
Clin Chim Acta; 2020 Feb; 501():174-178. PubMed ID: 31758936
[TBL] [Abstract][Full Text] [Related]
14. Validation of the prostate health index in a predictive model of prostate cancer.
Sanchís-Bonet A; Barrionuevo-González M; Bajo-Chueca AM; Pulido-Fonseca L; Ortega-Polledo LE; Tamayo-Ruiz JC; Sánchez-Chapado M
Actas Urol Esp (Engl Ed); 2018; 42(1):25-32. PubMed ID: 28811062
[TBL] [Abstract][Full Text] [Related]
15. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
[TBL] [Abstract][Full Text] [Related]
16. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
[TBL] [Abstract][Full Text] [Related]
18. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
[TBL] [Abstract][Full Text] [Related]
19. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
[TBL] [Abstract][Full Text] [Related]
20. Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?
Sanchis-Bonet A; Barrionuevo-González M; Bajo-Chueca A; Morales-Palacios N; Sanchez-Chapado M
Urol Int; 2018; 100(2):146-154. PubMed ID: 29346783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
